COMPANY PROFILE

Sartorius

Sartorius collaborates with the life sciences and biopharmaceutical sectors, supporting research and manufacturing advancements

Göttingen, GermanyFounded 1870Marketing

Valuation $23B Market cap · 2026

Revenue $3.44B Latest reported FY

EBITDA $1.07B Latest reported FY

About Sartorius

Sartorius, a name synonymous with precision and innovation in the biopharmaceutical industry, traces its roots back to 1870. Founded by Florenz Sartorius in Göttingen, Germany, the company began its journey by producing precision balances. Over the decades, Sartorius expanded its expertise and product offerings, becoming a key player in laboratory and bioprocessing technologies.

In the 20th century, Sartorius made significant strides by diversifying into various scientific and industrial sectors. This diversification laid the groundwork for its future growth and adaptation to the rapidly evolving demands of the biopharmaceutical industry.

A pivotal moment in Sartorius's history came in 1990 when it went public, marking a new era of expansion and innovation. This move allowed Sartorius to invest in cutting-edge technologies and expand its global footprint. The company's commitment to innovation was further demonstrated through strategic acquisitions, such as the purchase of BioOutsource Ltd. in 2015, which enhanced its service offerings in the biopharmaceutical sector.

Today, Sartorius is renowned for its contributions to the development and production of biotech drugs and vaccines. With two major divisions—Bioprocess Solutions and Lab Products & Services—Sartorius continues to support its customers in navigating the complexities of biopharmaceutical production. The company's journey from a small precision balance manufacturer to a global leader in biopharmaceutical solutions is a testament to its enduring commitment to innovation and excellence.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 1870
Headquarters: Göttingen, Germany
Listing: IPO 2002
Employees: 4,468
Open positions: None listed
Dealroom signal: 27.0/100
Industry: Health, Marketing
Sector: Marketing, Biotechnology, Tech for Biotech and Pharma, Biotech and Pharma, EIT KIC Partners, observatoire healthtech
Business model: Manufacturing
Client focus: b2b
Investment activity: 14 companies, latest Sep 2025
Capital deployed: $7.6M
Preferred round: ACQUISITION
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO DEBT✓Debt	May 2026	$550M	—	Undisclosed	↗
IPO✓Exit	Jan 2002	$0	—	Undisclosed	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026	$3.4B	+5.4%	$1.1B	31.1%	$415M	12.1%	$146M
2025	$3.3B	+6.7%	$932M	28.5%	$292M	9%	$146M
2024	$3.1B	+0.2%	$775M	25.3%	$193M	6.3%	$159M
2023	$3.1B	-20.5%	$765M	25.1%			$142M
2022	$3.8B	+21%	$1.4B	35.3%
2021	$3.2B	+51.1%	$907M	28.6%
2020	$2.1B	—	$686M	32.7%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Sartorius website traffic

Latest recorded traffic for Sartorius is 270K monthly website visits, up 35% over the last three months. Sartorius's team grew 0% over the past year.

Latest monthly visits270K 3-month web change+35% 1-year team growth0%

Monthly website visitsDec 2018–Oct 2020

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
GBGenerare BioscienceBioactive molecule discovery platform from microbial DNA	Paris, France	Operational	38	$28M	$88M
MEMEDIMPRINTTissue fingerprinting as an innovation to better diagnose and treat brain diseases	Grenoble, France	Operational
ELEpigene LabsHelping cancer researchers develop new treatments and drugs by providing them with data-driven insights	Paris, France	Operational
PBProxima BioFormerly VantAI. Proximity therapeutics hijacking cellular machinery for protein degradation	New York City, United States	Operational
RDRX DynamicsDeveloping CombiANT, a technology that tests interactions between bioactive compounds, identifying synergy or antagonism in drug combinations	Uppsala kommun, Sweden	Operational
BIBioResearchAIA cutting-edge research platform where you can experience AI technology being applied to pharmaceutical and biotech research at the forefront	Seoul, South Korea	Operational
XBXellar BiosystemsAccelerating drug discovery through human-mimetic organ-on-a-chip technology, high-fidelity 3D disease models, and AI-powered spatiotemporal profiling.	Boston, United States	Operational
LILiveDropDevelops advanced microfluidic instruments for high-throughput biological screening and droplet-based research	Liège, Belgium	Operational